Peptides and Huntington’s Disease: Neuropeptide Research

Understanding Huntington’s Disease

Huntington’s disease is caused by an expansion of a CAG trinucleotide repeat in the HTT gene, leading to production of a mutant huntingtin protein that progressively destroys neurons — particularly in the striatum and cortex. Symptoms include uncontrolled movements (chorea), cognitive decline, and psychiatric disturbances. HD is invariably progressive and fatal. Current therapies address symptoms but do not slow underlying neurodegeneration.

The molecular mechanisms driving HD neurodegeneration include mitochondrial dysfunction, impaired autophagy, neuroinflammation, and glutamate excitotoxicity — pathways that overlap considerably with other neurodegenerative diseases, which is why compounds studied in Alzheimer’s and Parkinson’s research are also being evaluated in HD contexts.

Semax and Neuroprotection in HD Models

Semax is a synthetic analogue of ACTH(4-7) developed in Russia that robustly upregulates BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor). In HD, BDNF levels in the striatum are severely depleted — mutant huntingtin disrupts BDNF transcription and transport. Striatal BDNF deficiency is one of the leading hypotheses for why striatal neurons die preferentially in HD. Semax’s ability to restore or maintain BDNF levels in rodent neurodegeneration models makes it a biologically plausible candidate for HD neuroprotection research, though HD-specific Semax data are limited.

View Semax →

Selank and Neuroinflammation

Selank is a synthetic heptapeptide analogue of tuftsin with anxiolytic and nootropic properties. It has been shown to modulate IL-6 and TNF-α signaling — cytokines elevated in HD brain tissue. Neuroinflammation, particularly microglial activation in the striatum, is now recognized as a significant contributor to HD progression rather than a mere secondary response. Selank’s anti-inflammatory peptide profile has drawn preclinical interest in HD models alongside its established neurological effects.

View Selank →

Cerebrolysin and Striatal Protection

Cerebrolysin contains neurotrophic fragments with BDNF- and FGF-like activity. In models of striatal excitotoxicity — a reasonable proxy for HD-related striatal damage — Cerebrolysin has shown neuroprotective effects, reducing neuronal loss and preserving motor function. Its multi-target neurotrophic activity may address several HD pathways simultaneously, though this broad action also makes it harder to study mechanistically.

Key HD Pathways Under Investigation

• BDNF restoration: Semax and Cerebrolysin address the BDNF deficit central to striatal neuron death
• Neuroinflammation reduction: Selank modulates inflammatory cytokines elevated in HD tissue
• Excitotoxicity protection: Multiple peptides reduce glutamate-mediated neuronal damage
• Autophagy support: Some neurotrophic peptides may indirectly support mutant protein clearance pathways

Research Context and Limitations

HD is uniquely challenging because it is a single-gene disease with a known genetic cause — yet the cascade of downstream effects is extraordinarily complex. Animal models (particularly knock-in mouse models) replicate many aspects of HD but are imperfect. No peptide discussed here has undergone HD-specific clinical trials. These findings are from related neurotoxicity and neurodegeneration models and should be interpreted accordingly.

Written by the NorthPeptide Research Team

References